Corgentech has reported top-line clinical data from a Phase II trial of pain drug candidate 4975, which demonstrated pain reduction in patients after total knee replacement surgeries.
4975 is a new long-acting, non-opioid drug being developed for site-specific, moderate-to-severe pain. The drug showed pain reduction at all pre-specified time intervals in the study, with statistically significant pain relief on the first and the fourteenth days.
